A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
Stopped early · Phase 1/Phase 2
Conditions studied: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
In brief
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the second phase, participants will receive the selected dose(s) based on the results in the first phase.
Key facts
- Study ID
- NCT06561425
- Run by
- Lakefront Biotherapeutics NV
- People needed
- 130
- Starts
- 2022-03-09
- Expected to finish
- 2026-05-27
- Last updated by the study team
- 2026-06-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Tufts Medical Center — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Antwerp University Hospital — Edegem, Belgium
- UZ Leuven — Leuven, Belgium
- CHU De Liège — Liège, Belgium
- Algemeen Ziekenhuis Delta — Roeselare, Belgium
- Cliniques Universitaires Saint-Luc — Woluwe-Saint-Lambert, Belgium
- Helsingin Yliopistollinen Sairaala (HUS) — Helsinki, Finland
- Academisch Medisch Centrum (Amsterdam UMC) — Amsterdam, Netherlands
- Leiden University Medical Center — Leiden, Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) — Rotterdam, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.